linjc16/ctgov huggingface dataset:
Body Contouring After Bariatric Surgeries in Jordan

Study Overview
=================
Brief Summary
-----------------
This study aimed to describe Jordanians' awareness and knowledge of body-contouring surgeries and estimate their prevalence. Additionally, we aimed to identify the limitations reported by our population and compare them with those reported in the literature.

Detailed Description
-----------------
We aimed to reach out to 351 patients who underwent bariatric surgery at JUH as well as an additional 100 patients who underwent BS at one of the largest private medical facilities in Amman between January and June of 2021. We distributed a validated questionnaire to all patients. Of the 451 patients, 305 completed the questionnaire (response rate: 67.6%). The inclusion criteria were age 13-63 years, BS type (sleeve gastrectomy or Roux-en-Y bypass), and completion of the questionnaire. Responses that did not meet these criteria or contained duplicates were excluded (n=11). The remaining 294 responses were collected and entered into a database for the analysis.Three main variables were assessed in each group in addition to multiple other observations. The main variables were sex, marital status, and employment status.

Official Title
-----------------
Ody Contouring After Bariatric Surgeries in Jordan: Awareness, Prevalence, and Challenges

Conditions
-----------------
Body Contouring

Intervention / Treatment
-----------------
* Other: Assessment of knowledge and behaviour


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 13-63 years Bariatric surgery type (LSG or RYGB) Exclusion Criteria: Incomplete or duplicate reponses Bariatric surgery ype (Gastric band)

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 63 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>Participants who didn't undergo body contouring surgery after bariatric surgery. | Other: Assessment of knowledge and behaviour<br>* Assessment of knowledge and behaviour<br>|
| Group B<br>Participants who underwent body contouring surgery after bariatric surgery. | Other: Assessment of knowledge and behaviour<br>* Assessment of knowledge and behaviour<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Body contouring surgeries after bariatric surgeries |  | 07/2017-06/2021 |
Perfluorooctyl Bromide Which Empowers the Liquid to Flat the Detached Retina and Displace the Underneath Fluids Anteriorly

Study Overview
=================
Brief Summary
-----------------
Perfluorohexyloctaneis Essential for Repositioning Giant Retinal Breaks and Can be Used for Removal of Subretinal Fluid as Well as Stabilization of the Retina to Offset

Official Title
-----------------
Perfluorooctyl Bromideessential for Repositioning Giant Retinal Breaks and Can be Used for Removal of Subretinal Fluid as Well as Stabilization of the Retina to Offset

Conditions
-----------------
Retinal Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Is 20 years or older Has been diagnosed with Keratoconus; Has no other active ocular disease; Is not pregnant or nursing; Exclusion Criteria: Is under the age of 20 Has best corrected visual acuity outside 20/400; Pregnant or nursing at the time of enrollment in the study;

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| eye surgery ,Vitreoretinal Surgery and Related Ocular Inflammation<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| flat the detached retina and displace the underneath fluids anteriorly | the effect of Perfluorooctyl Bromide on the retina ,under ophthalmic microscope check the flatted retina | Base line |
Patients With Higher BMI Produces More Postoperative Drainage Volume and Length of Stay in Cross-Sectional Study

Study Overview
=================
Brief Summary
-----------------
Partial knee arthroplasty theoretically produces less blood loss compared to total knee arthroplasty (TKA) due to a lesser invasive procedure. Medial unicompartmental knee arthroplasty (UKA) is the most common partial knee arthroplasty performed due used due to the most commonly impacted medial knee. This study compared the postoperative drainage volume and length of stay (LOS) of TKA vs UKA and evaluated its comparison with patient characteristics.

Detailed Description
-----------------
Theoretically, UKA will produce less blood loss due to a shorter skin incision, quadriceps sparing muscle approach, persistence of cruciate ligaments, and less femorotibial dislocation.7 However, studies investigating drainage volume in UKA are still limited. In this study, we compared the drainage volume of patients undergoing TKA vs UKA and evaluated several parameters that contributed the production. This study has not received any funding or grant.

Official Title
-----------------
Patients With Higher BMI Produces More Postoperative Drainage Volume and Longer Length of Stay in Cross-Sectional Study: a Comparison of Total vs Partial Knee Arthroplasty

Conditions
-----------------
Osteoarthritis, Knee

Intervention / Treatment
-----------------
* Procedure: Knee Replacement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: grade 4 Osteoarthritis Exclusion Criteria: previous trauma infection blood coagulation disorder

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TKA (Total Knee Arthroplasty) procedure<br>Total Knee Arthroplasty | Procedure: Knee Replacement<br>* Total vs Partial Knee Replacement<br>|
| UKA (Uni Knee Arthroplasty) procedure<br>Uni Knee Arthroplasty | Procedure: Knee Replacement<br>* Total vs Partial Knee Replacement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drainage Volume | total drainage volume | 3-5 days post op | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| LOS | length of stay | pre-op until drainage removed, 3-6 days post op |
Comparison of Same Morning vs Previous Evening Dosing Regimen for Assessment of Quality of Bowel Preparation for Colonoscopy Under Anesthesia

Study Overview
=================
Brief Summary
-----------------
220 patients are allocated randomly to the morning group (am group) or the afternoon group (pm group) and assessed by quality of bowel preparation and residual volume gastric residue.

Official Title
-----------------
Comparison of Same Morning vs Previous Evening Dosing Regimen for Assessment of Quality of Bowel Preparation Under Anesthesia

Conditions
-----------------
Bowel Preparation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients are able to follow the instructions of bowel preparation and have good ability of walking at least an hour. Exclusion Criteria: Clinical diagnosis of obstruction of bowel and sever renal and heart disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ottawa score | Two nurses observe cleaning of three parts of colon and give a score for each. | a day | 
| gastric residual volume | Gastric contents are suctioned and measured. | 30 minutes | 
| colonic residual volume | Colonic fluids are suctioned and measured. | 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| reflux | incidence of reflux during both the EGD and colonoscopy | 60mins | 
| adenoma detection rate | percentages of patients screened with colonic adenoma in total patients | a day |
Assessment of Osseointegration Properties of Nano-Hydroxy Apatite Coated Titanium Implant

Study Overview
=================
Brief Summary
-----------------
the purpose of this trial is to evaluate the osseointegration properties of nano-hydroxy apatite coated titanium implants in posterior maxilla. 30 patients will be included in this trial divided into two groups, control and intervention. Primary and secondary implant stability will be measured

Official Title
-----------------
Assessment of Osseointegration Properties of Nano-Hydroxy Apatite Coated Titanium Implant Versus Sandblasted Large Thread Acid Etched Implants in Posterior Maxilla. A Randomized Clinical Trial

Conditions
-----------------
Implant Site Reaction

Intervention / Treatment
-----------------
* Other: nano-hydroxy apatite coated titanium implants
* Other: sandblasted large acid itched coated titanium implant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with missing at least one maxillary posterior tooth Patients free from any systemic disease Patients who approve to be included in the trial and sign the informed consent Patients with no intra-bony defect. Adults aged 18 years old and above Exclusion Criteria: Patients who are allergic to titanium Heavy smoker patient Patients receiving chemotherapy or radiotherapy Patients who refused to be included in the trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nano-hydroxy apatite arm<br>in this groups patients will receive nano-hydroxy apatite coated titanium implants | Other: nano-hydroxy apatite coated titanium implants<br>* titanium implants with surface treatment of nano-hydroxy apatite<br>|
| Active Comparator: SLA arm<br>in this group patients will receive sandblasted large thread acid etched titanium implants | Other: sandblasted large acid itched coated titanium implant<br>* titanium implants with SLA surface treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implant stability | implant stability will be measured by radiofrequency analysis | immediately post-operative | 
| Implant stability | implant stability will be measured by radiofrequency analysis | 4 weeks post-operative | 
| Implant stability | implant stability will be measured by radiofrequency analysis | 6 weeks post-operative | 
| Implant stability | implant stability will be measured by radiofrequency analysis | 12 weeks post-operative |
Turkish Isolated Coronary Ectasia Registry: The T-ICE Registry

Study Overview
=================
Brief Summary
-----------------
The T-ICE study is a prospective, observational study aiming to have information about the treatment and long-term prognosis of patients with isolated coronary artery ectasia.

Detailed Description
-----------------
Coronary artery ectasia is a localized or diffuse enlargement of the coronary artery lumen ≥1.5-2 times relative to the normal segment. It is often associated with coronary artery stenosis. Some patients have coronary artery ectasia without stenosis. This condition is called as isolated coronary artery ectasia. There is data other than retrospective studies with a small number of cases on the clinical significance, prognosis and treatment of isolated coronary ectasia in patients with or without acute coronary syndrome. Therefore, the treatment of patients with isolated coronary ectasia is not evidence-based and is based on the clinical judgment of physicians. The aim of this prospective observational study is to evaluate the treatment and prognosis of the isolated coronary artery ectasia. The second aim is to compare the prognosis of isolated coronary ectasia with the coronary artery disease.

Official Title
-----------------
Turkish Isolated Coronary Ectasia Prospective Cohort Study: the T-ICE Registry

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Isolated coronary artery ectasia (without ≥20% stenosis in any coronary artery ≥2 mm in diameter). All patients with isolated coronary ectasia with or without acute coronary syndrome will be included. Patients aged ≥18 years. Patients with discrete coronary artery aneurysm will be included. Exclusion Criteria: Life expectancy <24 months Patients with ≥20% stenosis in a vessel ≥2 mm in diameter.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Isolated coronary ectasia<br>Includes the patients with isolated coronary artery ectasia without coronary stenosis. | |
| Coronary artery disease<br>Includes the patients with ≥50% stenosis in a vessel ≥2 mm in diameter. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiovascular and cerebrovascular events | A composite endpoint of death, myocardial infarction, unstable angina, stroke, and coronary revascularization. | Five years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiovascular events | A composite endpoint of cardiovascular death, myocardial infarction, unstable angina, and coronary revascularization. | Five years |
Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France

Study Overview
=================
Brief Summary
-----------------
This was a non-interventional, retrospective, cross-sectional, descriptive study, conducted on the National Health Data System (Système National des Données de Santé, SNDS). The study did not modify the doctor-patient relationship, nor the management or follow-up of patients. Patients with dispensation of canakinumab for gouty arthritis were selected over the period from 08 April 2018 to 07 April 2020; index date was defined as date of the first dispensation of canakinumab in community pharmacy during study period. Patients were described at index date. Medical history and comorbidities, and previous treatments for gouty arthritis were assessed during 3 years prior to index date. Co-treatments of interest for which standard treatments for gouty arthritis were contraindicated or required precautions for use were assessed during 6 months prior to index date.

Official Title
-----------------
Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France

Conditions
-----------------
Gouty Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Received at least one reimbursement of Ilaris® from 08 April 2018 to 07 April 2020. Benefited from at least one of the following healthcare consumptions during 3 years prior to index date: o At least one hospitalization with a main diagnosis or a related diagnosis in a Medical Unit Summary or a significant associated diagnosis in a Standardized Discharge Summary corresponding to the International Classification of Diseases, 10th Revision (ICD-10) code: M10.0 Idiopathic gout M10.1 Saturnine gout M10.2 Medicated gout M10.3 Gout due to impaired renal function M10.4 Other secondary gout M10.9 Gout, unspecified And/or an active long-term disease (Affection Longue Durée, ALD) with an ICD-10 code: M10 Gout And/or at least one dispensation of colchicine and urate-lowering therapy (allopurinol and/or febuxostat and/or benzbromarone and/or probenecid) at any time. Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients treated with canakinumab in France for the treatment of gouty arthritis |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean age of patients |  | 3 years | 
| Number of male patients |  | 3 years | 
| Geographic location of patients |  | 3 years | 
| Number of patients with previous treatments for gouty arthritis |  | 3 years | 
| Medical history of patients |  | 3 years | 
| Number of patients with comorbidities |  | 3 years |
Hyperosmolality and Acute Kidney Injury After Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
The goal of this randomized controlled trial is to test if a hyperosmolar prime solution used for cardiopulmonary bypass increases the risk for acute postoperative kidney injury.

Detailed Description
-----------------
Two-hundred cardiac surgical patients were randomised into two groups based on the osmolality level of the prime solution used for cardiopulmonary bypass. The high osmolality group (966 mOsm) received a prime solution containing Ringer-Acetate 1000 ml + Mannitol 400 ml (60 g) + Sodium-Chloride 40 ml (160 mmol) and Heparin 2 ml (10 000 IU), while the reference group with normal osmolality (388 mOsm) received a prime solution containing Ringer-Acetate 1400 ml and Heparin 2 ml (10 000 IU).

Official Title
-----------------
Hyperosmolar Priming Solution for Cardiopulmonary Bypass May Increase the Risk for Postoperative Acute Kidney Injury: Results From Double-blinded Randomised Controlled Trial

Conditions
-----------------
Acute Kidney Injury, Osmolality Disturbance, Cardiopulmonary Bypass

Intervention / Treatment
-----------------
* Drug: HighOsmo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient eligible for routine cardiac surgical procedures requiring cardiopulmonary bypass. Exclusion Criteria: Patients requiring acute surgical intervention within 24 h or profound hypothermia during surgery were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomisation into two groups based on the osmolality level in the priming solution used for cardiopulmonary bypass.
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: NormOsmo<br>This group received a priming solution with normal osmolality. | |
| Active Comparator: HighOsmo<br>This group received a priming solution with high osmolality | Drug: HighOsmo<br>* This group received a priming solution with high osmolality<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative Acute Kidney Injury | Defined according to the KDIGO definition | Three days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiopulmonary Bypass, Priming Solution, Plasma Osmolality, Acute Kidney Injury
Oral Cancer Screening in Workplace: a Cross-sectional Study

Study Overview
=================
Brief Summary
-----------------
Employees are to be all screened for oral cancer in work place.

Official Title
-----------------
An Experience of Oral Cancer Screening in Workplace: a Cross-sectional Study

Conditions
-----------------
Oral Cancer

Intervention / Treatment
-----------------
* Other: conventional oral examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults Exclusion Criteria: refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Employees in Ahram Canadian university<br> | Other: conventional oral examination<br>* conventional oral examination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of lesion: oral cancer or oral potentially malignant lesions | detected on examination | upon study completion; an average of 3 months |
Finding Patterns In Clinical Trial Experiences of Patients With Eczema

Study Overview
=================
Brief Summary
-----------------
Historically, participation in clinical trials has been skewed towards certain groups. However, research on the factors that influence participation, both positive and negative, is limited. Eczema clinical trial patients help us identify these factors by sharing trial experiences during the course of the observational medical study. This study will include a diverse group of participants to gather a wide range of information on clinical trial experiences. The collected data will then be used to benefit future eczema patients who are considering participating in a clinical study.

Official Title
-----------------
An In-depth Study Assessing Eczema Patients Experiences in Medical Trials

Conditions
-----------------
Eczema

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has been diagnosed with eczema Patient is 18 years old Patient has self-identified as planning to enroll in an observational clinical study Exclusion Criteria: Patient does not understand, sign, and return consent form Patient is pregnant Inability to perform regular electronic reporting

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to enroll in a clinical trial for eczema. |  | 3 months | 
| Rate of patients who remain in an eczema clinical trial to completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Eczema